Pharma Products Mergers and Acquisitions in the Pharma-Biotech Panorama Article by Andrea V. Smith The past ten years have proven challenging for the pharma industry, witnessing a large number of mergers and acquisitions within it. Recently, this tendency has been reinforced with what may be called super mergers and acquisitions. It is obvious that the financial reality, marked by an economic deceleration and credit compression, is behind this, but it is not the only important factor. Big pharma has been dealing for a long time with issues regarding patent expiry of blockbuster molecules, regulatory obstacles, generics competition, under utilization of resources, and declining product pipeline due to low R&D productivity, among others. All these factors, along with the current economic reality, have caused major lowering of stock market values, creating the perfect … Read entire article »